AI assistant
GlaxoSmithKline PLC — Director's Dealing 2016
Jul 18, 2016
5262_ffr_2016-07-18_193f171d-ecfa-4eb4-af3f-79e7dc37bf6c.zip
Director's Dealing
Open in viewerOpens in your device viewer
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending 18 July 2016
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc (the ' Company ')
Transaction notification
| 1. — a) | Details of PDMR/person closely associated with them ('PCA') — Name | Mr S Dingemans | |
|---|---|---|---|
| b) | Position/status | CFO | |
| c) | Initial notification/ amendment | Initial notification | |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | GlaxoSmithKline plc | |
| b) | LEI | 5493000HZTVUYLO1D793 | |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||
| a) | Description of the financial instrument | Ordinary shares of 25 pence each ISIN: GB0009252882 | |
| b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016, on shares held through the Company's ShareReward Plan. | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £16.6373 | 14 | ||
| d) | Aggregated information Aggregated volume Price | n/a (single transaction) | |
| e) | Date of the transaction | 2016-07-14 | |
| f) | Place of the transaction | London Stock Exchange (XLON) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
GlaxoSmithKline plc
(Registrant)
Date: July 18, 2016
By: VICTORIA WHYTE
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc
page break